Kiromic BioPharma (KRBP) announced that it has entered into a settlement agreement with the U.S. SEC, resolving the previously disclosed SEC investigation arising from the non-disclosure by Kiromic’s prior executive management of the clinical holds placed on the investigational new drug applications the company filed with the U.S. Food and Drug Administration in May 2021. The IND applications pertained to ALEXIS-PRO-1 and ALEXIS-ISO-1. In light of the company’s self-reporting, prompt remediation and cooperation, the SEC has determined not to impose a civil penalty on the company and there are no ongoing undertakings in connection with the settlement.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
